ERBB2 and breast cancer: More than one-third of Her2 positive or “triple-negative" (estrogen receptor‐negative, progesterone receptor‐negative, and Her2‐negative) breast cancer patients will progress to brain metastasis, which has a poor prognosis with a median survival time of fewer than 12 months [2, 3].